WHAT IS CLAIMED IS:

~~1. A composition capable of causing the appearance of IL-12 in plasma, the composition essentially consisting of:~~

~~a foreign antigen;~~

~~at least one Th1 cytokine; and~~

~~a DC maturation molecule.~~

~~2. The composition of claim 1 where the foreign antigen is an alloantigen.~~

~~3. The composition of claim 1 where the Th1 cytokine is one or more of the following: IL-1, IL-2, IL-6, IL-8, IL-15, Interferon-gamma, TNF-alpha, GM-CSF.~~

~~4. The composition of claim 1 where the DC maturation molecule is CD40L and/or FasL.~~

~~5. The composition of claim 2 where the alloantigen is on a living T-cell.~~

~~6. The composition of claim 5 where the T-cells are CD4+ cells or Th1 cells.~~

~~7. The composition of claim 6 where the Th1 cell is activated.~~

~~8. The composition of claim 7 where the Th1 cells are activated by cross-linking CD3 and CD28.~~

~~9. The composition of claim 8 where the activated Th1 cells secrete one or more of the following Th1 cytokines: IL-2, IFN-gamma and GM-CSF.~~

~~10. The composition of claim 9 where the activated Th1 cells express the DC maturation molecule CD40L and/or FasL on their surface.~~

~~11. The composition of claim 1 where the components are immobilized on a surface.~~

~~12. The composition of claim 11 where the surface is biodegradable.~~

~~13. The composition of claim 5 where the living T-cells are packaged in a syringe or flexible container.~~

~~14. The composition of claim 13 where the cells are at a concentration of 1 x 10^7 cells/ml or greater.~~

~~15. The composition of claim 14 where the cells are suspended in a non-nutrient media.~~

~~16~~1. Use of a composition comprising of allogeneic cells wherein at least a portion of the cells are activated T-cells in the manufacture of a medicament for increasing plasma levels of endogenous IL-12 in a patient;

wherein the composition is to be administered to the patient; wherein the levels of endogenous IL-12 is to be monitored and wherein the composition is to be re-administered if sufficient levels of endogenous IL-12 are not detected in the plasma of the patient.

217. The use of claim 116 wherein the ~~detection~~detactable level of IL-12 is not toxic to the patient.

318. The use of claim 116 wherein the activated T-cells are CD4+ cells.

419. The use of claim 318 wherein the activated CD4 cells are Th1 cells.

520. The use of claim 419 wherein the Th1 cells are activated by cross-linking CD3 and CD28.

621. The use of claim 116 wherein administration of the composition increases the level of IFN-gamma in the patient and/or the Th1 response.

722. The use of claim 116 wherein the level of IL-12 in the plasma of the patient is at least about 5000pg/ml.

8. The use of claim 1, wherein the patient has cancer or an infectious disease.

239. Use of a composition comprising allogeneic cells wherein at least a portion are activated T-cells, in the manufacture of a medicament for treating a disease in a patient, wherein the T-cells are activated by cross-linking one or more agents bound to the cell surface moieties on the T-cells; wherein the composition is to be administered to the patient; wherein the levels of endogenous IL-12 in the patient's plasma is to be monitored; and wherein the composition is to be re-administered if endogenous IL-12 is not detected in the plasma of the patient.

2410. The use of claim 239 wherein the disease is cancer or is a result of a pathogenic infection.

2511. The use of claim 239 wherein the readministration is to be repeated until the concentration of the endogenous IL-12 is detectable.

2612. ~~A~~Use of a therapeutic composition comprising activated allogeneic T cells in the manufacture of a medicament for increasing the endogenous levels of IL-12 ~~comprising activated allogeneic T cells~~ wherein the administration of the ~~composition~~medicament leads to detectable levels of endogenous IL-12 in the plasma of a patient without toxicity to the patient.

2713. The use~~composition~~ of claim 2613 wherein the patient has cancer or an infectious disease.

2814. The use~~composition~~ of claim 2613 wherein the T-cells are CD4+ cells.

2915. The use~~composition~~ of claim 2613 wherein the T-cells are activated by cross-linking one or more agents that are bound to the cell surface moieties on the T-cells.

3016. The composition of claim 2612 wherein the one or more agents are monoclonal antibodies such as anti-CD3 and anti-CD28 monoclonal antibodies.